Based on these observations, our working hypothesis is that the vertical and complete inhibition of the PI3K/AKT/mTOR/HIF-1α axis with mTOR catalytic inhibitors and low doses of irinotecan may have a significant antitumor effect by reducing cancer cell viability and migration, as well as risk of recurrence of metastases. Here, MTOR is linked to cancer.